CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle.Additionally, they control mRNA processing, transcription, and nerve cell differentiation. With molecular weights between 34 and 40 kDa, CDKs are relatively small proteins that only contain the kinase domain. In fact, when their CDK gene has been replaced with the homologous human gene, yeast cells can proliferate normally. A CDK by definition binds the control protein cyclin. Only the cyclin-CDK complex is an active kinase; CDK lacks much kinase activity on its own.
Around 20 Cyclin-dependent kinases (CDK1-20) have been identified as of yet. While CDK 7, 8, 9 and 11 are linked to transcription, CDK1, 4, and 5 are involved in the cell cycle.
The majority of CDK regulation occurs post-translationally, and CDK levels are essentially constant throughout the cell cycle. The majority of knowledge about CDK structure and function is based on CDKs from vertebrates (CDC2 and CDK2), S. pombe (CDC28), and S. cerevisiae (Cdc2). Cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and CDK inhibitory subunit (CKI) binding are the four main mechanisms of CDK regulation.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V102173 | (+)-Atuveciclib | 1414943-94-4 | (+)-Atuveciclib is an isomer of Atuveciclib (Racemate). | |
V4163 | (+)-BAY-1251152 | 1610358-56-9 | BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. | |
V77392 | (2S,3R)-Voruciclib hydrochloride | rel-(2S,3R)-Voruciclib HCl is an enantiomer of Voruciclib HCl. | ||
V52146 | (E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) | 740841-15-0 | (E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and specific GSK-3α/β inhibitor (antagonist) with IC50 of 10 nM. | |
V55086 | (E/Z)-TG003 | 300801-52-9 | (E/Z)-TG003 is the racemate of (Z)-TG003 and (E)-TG003. | |
V84546 | (E/Z)-THZ1 dihydrochloride | 2095433-94-4 | ||
V52837 | (E/Z)-Zotiraciclib ((E/Z)-TG02; (E/Z)-SB1317) | 937270-47-8 | (E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM respectively. | |
V50450 | (E/Z)-Zotiraciclib HCl-TG02 HCl | 1321626-25-8 | (E/Z)-Zotiraciclib HCl (TG02 HCl) is a novel and potent CDK2, JAK2, and FLT3 inhibitor with the potential for the treatment of cancer. | |
V87892 | (R)-(+)-O-Demethylbuchenavianine | 1364123-68-1 | (R)-(+)-O-Demethylbuchenavianine is a cyclin-dependent kinase (CDK) inhibitor. | |
V40461 | (R)-CR8 triHCl | 1786438-30-9 | (S)-CR8 trihydrochloride, ananalog of Roscovitine, is a novel, potent 2nd-generation cyclin-dependent kinase (CDK) inhibitor, also acting as a molecular glue degrader that depletes cyclin K. | |
V69796 | (R)-DRF053 dihydrochloride | 1241675-76-2 | (R)-DRF053 di-HCl is a potent inhibitor of casein kinase 1 (CK1), CDK1/cyclin B, and CDK5/p25 with IC50s of 14 nM, 220 nM, and 80 nM, respectively. | |
V75982 | (R)-PROTAC CDK9 ligand-1 | 2411021-95-7 | (R)-PROTAC CDK9 ligand-1 (compound 19.4) is a CDK9-targeted degrader that may be utilized to prepare PROTACs with anti-tumor activity. | |
V3635 | (rel)-MC180295 | 2237942-08-2 | (rel)-MC180295 is a novel, potent and selective CDK9-Cyclin T1 inhibitor with an IC50 of 5 nM and with broad anti-cancer activity in vitro. | |
V90764 | (S)-(-)-O-Demethylbuchenavianine | 91147-18-1 | (S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoid alkaloid. | |
V55070 | (S)-GFB-12811 | 2757672-69-6 | (S)-GFB-12811 (compound 596) is a potent and specific CDK5 inhibitor (antagonist) with IC50 of less than 10 nM. | |
V92044 | (S)-PHA533533 | 437982-89-3 | (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. | |
V101505 | (S)-Roscovitine | 186692-45-5 | (S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent CDK inhibitor that crosses the blood-brain barrier. | |
V4202 | (±)-BAY-1251152 | 1610358-53-6 | BAY-1251152 is a racemic mixture of BAY-1251152 which is a novel, potent and highly selectivePTEF/CDK9 inhibitor. | |
V84078 | 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) | 137254-39-8 | ||
V52503 | 3-Methylthienyl-carbonyl-JNJ-7706621 | 443798-09-2 | 3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and specific cyclin-dependent kinase (CDK) inhibitor (antagonist) with IC50s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. |